Our team has developed a hyaluronic acid-drug conjugation technology to create a polymer nanoparticle drug delivery system. It significantly enhances the grafting efficiency of hydrophobic drugs onto hyaluronic acid, reduces byproduct formation, and improves solubility. These hyaluronic acid conjugates, with targeted delivery and immune modulation properties, have been licensed and advanced to USFDA Phase II clinical trials, along with several preclinical drug and immune adjuvant developments.

"Highly Efficient Conjugation:: This technology increases the hydrophobic drug reaction efficiency to over 90%.
 
 Targeted Delivery: This technology targets specific cancer cell or immune cell, achieving precision medicine.
 
 Controlled Drug Release: Provides a controlled release solution tailored to the target environment.
 
 Safe Immune Activation: PEG free adjuvant to overcome the material safety issues of traditional O/W nano emulsion and lipid nanoparticles adjuvants."

This hyaluronic acid conjugation technology provides broad application prospects in the biomedical industry, especially in cancer treatment, vaccine adjuvant, and localized inflammation applications. With its advantages, this technology can significantly enhance therapeutic efficacy. Additionally, the first drug developed using this technology, CA102N, has been approved for Phase II clinical trials in the United States, demonstrating its extensive commercial value and development potential.